Dyadic International (DYAI) Competitors

Protalix BioTherapeutics (NYSE:PLX) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

Which has more volatility and risk, PLX or DYAI?

Protalix BioTherapeutics has a beta of -0.21, suggesting that its stock price is 121% less volatile than the S&P 500. Comparatively, Dyadic International has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.

Do analysts rate PLX or DYAI?

Protalix BioTherapeutics presently has a consensus price target of $15.00, suggesting a potential upside of 886.84%. Dyadic International has a consensus price target of $6.00, suggesting a potential upside of 650.00%. Given Protalix BioTherapeutics' higher probable upside, equities analysts clearly believe Protalix BioTherapeutics is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Dyadic International	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has higher earnings and valuation, PLX or DYAI?

Protalix BioTherapeutics has higher revenue and earnings than Dyadic International. Dyadic International is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$59.76M	2.02	$8.31M	$0.04	38.00
Dyadic International	$3.34M	7.20	-$5.81M	-$0.19	-4.21

Does the media refer more to PLX or DYAI?

In the previous week, Protalix BioTherapeutics and Protalix BioTherapeutics both had 9 articles in the media. Protalix BioTherapeutics' average media sentiment score of 0.98 beat Dyadic International's score of 0.36 indicating that Protalix BioTherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protalix BioTherapeutics	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is PLX or DYAI more profitable?

Protalix BioTherapeutics has a net margin of -21.03% compared to Dyadic International's net margin of -134.84%. Protalix BioTherapeutics' return on equity of -30.89% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Dyadic International	-134.84%	-245.78%	-58.43%

Do insiders and institutionals have more ownership in PLX or DYAI?

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 6.5% of Protalix BioTherapeutics shares are held by company insiders. Comparatively, 29.5% of Dyadic International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Protalix BioTherapeutics beats Dyadic International on 8 of the 13 factors compared between the two stocks.